Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1, Drug Therapy, Combination, RNA, Viral, Anti-HIV Agents, Viral Load, remune
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Are receiving an anti-HIV drug combination that contains three drugs from at least two classes of anti-HIV drugs (such as protease inhibitors). Patients must have been receiving this drug combination for at least 6 months before study entry. Before beginning this drug combination, patients must have taken either no anti-HIV drugs or only one or two nucleoside analogues (NRTIs). Had a viral load between 5,000 and 100,000 copies/ml before beginning their current anti-HIV therapy. Have a viral load below 50 copies/ml while on their current anti-HIV therapy within 2 weeks before study entry. Have a CD4 count greater than 350 cells/mm3 at the time of study entry. Are at least 13 years old (consent of parent or guardian required if under 18).
Sites / Locations
- Agouron Pharmaceuticals Inc